Tara Smith 6/24/25 Tara Smith 6/24/25 RhizoKids 2025 Read More Tara Smith 4/10/25 Tara Smith 4/10/25 Q&A: Approved drugs versus supplements Read More Tara Smith 3/31/25 Tara Smith 3/31/25 MLD announces publication of RhizoQOL survey Read More Tara Smith 3/17/25 Tara Smith 3/17/25 First human safety and pharmacokinetic study of a plasmalogen augmentation therapy published by MLD Read More Tara Smith 1/16/25 Tara Smith 1/16/25 MLD announces plans for Rare Disease Day 2025 Read More Kaeli Knudsen 11/18/24 Kaeli Knudsen 11/18/24 MLD attending CORD Conference 2024 Read More Tara Smith 10/9/24 Tara Smith 10/9/24 MLD to present at World Orphan Drug Congress Europe Read More Tara Smith 7/24/24 Tara Smith 7/24/24 MLD publishes world's first chronic plasmalogen-deficient Alzheimer's mouse model Read More Tara Smith 5/8/24 Tara Smith 5/8/24 Patient-Focused Drug Development Session Read More Kaeli Knudsen 4/2/24 Kaeli Knudsen 4/2/24 MLD attending World Orphan Drug Congress 2024 Read More Shawn Ritchie 2/15/24 Shawn Ritchie 2/15/24 Rare Disease Day 2024 Coloring Contest Rules Read More Tara Smith 2/9/24 Tara Smith 2/9/24 MLD Presenting at AD/PD Conference Read More Shawn Ritchie 2/6/24 Shawn Ritchie 2/6/24 MLD Announces Completion of Dosing with Plasmalogen-precursor PPI-1011 in its Phase I Clinical Trial Read More Tara Smith 12/10/23 Tara Smith 12/10/23 Multiple ascending dose study of PPI-1011 begins dosing Read More Tara Smith 9/28/23 Tara Smith 9/28/23 MLD to attend Canadian Conference on Dementia Read More Tara Smith 6/6/23 Tara Smith 6/6/23 SASKATOON-BASED BIOPHARMA COMPANY MED-LIFE DISCOVERIES RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA TO BEGIN A HEALTHY ADULT PHASE 1 TRIAL FOR PPI-1011 Read More Kaeli Knudsen 4/12/23 Kaeli Knudsen 4/12/23 MLD attending Rhizokids International Conference in Alabama Read More Tara Smith 4/6/23 Tara Smith 4/6/23 MLD attending International Plasmalogen Conference Read More Tara Smith 9/6/22 Tara Smith 9/6/22 MLD attending BioPharm America Read More Tara Smith 6/28/22 Tara Smith 6/28/22 MLD attending World Orphan Drug Congress 2022 Read More Older Posts
Tara Smith 3/17/25 Tara Smith 3/17/25 First human safety and pharmacokinetic study of a plasmalogen augmentation therapy published by MLD Read More
Tara Smith 7/24/24 Tara Smith 7/24/24 MLD publishes world's first chronic plasmalogen-deficient Alzheimer's mouse model Read More
Shawn Ritchie 2/6/24 Shawn Ritchie 2/6/24 MLD Announces Completion of Dosing with Plasmalogen-precursor PPI-1011 in its Phase I Clinical Trial Read More
Tara Smith 12/10/23 Tara Smith 12/10/23 Multiple ascending dose study of PPI-1011 begins dosing Read More
Tara Smith 6/6/23 Tara Smith 6/6/23 SASKATOON-BASED BIOPHARMA COMPANY MED-LIFE DISCOVERIES RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA TO BEGIN A HEALTHY ADULT PHASE 1 TRIAL FOR PPI-1011 Read More
Kaeli Knudsen 4/12/23 Kaeli Knudsen 4/12/23 MLD attending Rhizokids International Conference in Alabama Read More
